Pfizer

Study confirms economic viability of orphan drugs positioned for unmet medical needs

Wednesday, August 22, 2012 12:35 PM

Orphan drugs, developed to treat rare diseases, have the potential to generate as much lifetime revenue as drugs used for more common health conditions, according to a study by Thomson Reuters’ intellectual property and science business.

More... »

Adventrx names Vetticaden as chief medical officer

Monday, August 20, 2012 04:01 PM

Adventrx Pharmaceuticals, a biopharmaceutical company based in San Diego, has appointed Santosh J. Vetticaden, M.D., Ph.D., as chief medical officer and senior vice president.

More... »

AstraZeneca, Pfizer enter agreement for OTC Nexium

Wednesday, August 15, 2012 09:41 AM

AstraZeneca, a global biopharmaceutical company, has entered into an agreement with Pfizer, a global research-based pharmaceutical company, for the over-the-counter (OTC) rights for Nexium (esomeprazole magnesium), a prescription drug currently approved to treat the symptoms of gastroesophageal reflux disease (GERD).

More... »

Nodality, Pfizer form multi-year collaboration on autoimmune disease

Thursday, August 9, 2012 02:16 PM

Nodality, a San Francisco-based personalized medicine biotech, has formed a strategic collaboration to provide proprietary single cell network profiling (SCNP) technology as a tool for the development of Pfizer compounds.

More... »

Prevention trial studies population 100% genetically predisposed to early-onset Alzheimer’s

Monday, August 6, 2012 07:00 AM

For the first time ever, an experimental drug is being tested to determine whether it can prevent Alzheimer’s disease in a population that has a 100% genetic predisposition for early onset of the disease. The study, to start next year, will be one of only a few being conducted to test prevention treatments for a genetically predestined disease.

More... »

Pfizer releases top-line data from phase III study of tofacitinib in RA

Friday, August 3, 2012 11:24 AM

Pfizer reported today top-line results from ORAL Start (A3921069), a phase III study of the investigational agent tofacitinib, a novel, oral Janus kinase (JAK) inhibitor for the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA).

More... »

Pfizer: endpoints not met in first phase III study of bapineuzumab for Alzheimer’s

Tuesday, July 24, 2012 02:54 PM

Pfizer has announced the co-primary clinical endpoints—change in cognitive and functional performance compared to placebo—were not met in the Janssen Alzheimer Immunotherapy R&D (Janssen AI)-led phase III trial of intravenous (IV) bapineuzumab in patients with mild-to-moderate Alzheimer's disease who carry the ApoE4 (apolipoprotein E epsilon 4) genotype (Study 302). Pfizer and Janssen AI are partners in the Alzheimer's Immunotherapy Program (AIP).

More... »

Conatus Pharmaceuticals appoints Morris as head of biostatistics

Thursday, July 19, 2012 08:16 AM

Conatus Pharmaceuticals, a San Diego-based privately held biopharmaceutical company focused on fibrotic disease and oncology, has appointed Mark F. Morris as head of biostatistics.

More... »

Pappas Ventures names Pat Gage to scientific advisory board

Monday, July 9, 2012 04:56 PM

Pappas Ventures, a life sciences investor based in Durham, N.C., has appointed L. Patrick Gage, PhD, to the company's scientific advisory board.

More... »

Pfizer grants ChemRar Group exclusive license to DPP-IVi T2D candidate

Friday, July 6, 2012 02:47 PM

Pfizer has granted  SatRx , a company belonging to Russian pharmaceutical investment and R&D group  ChemRar Hi-Tech Centre , exclusive development and marketing rights to for its DPP(1)-IVi compound, PF-00734200.

More... »